Backed by the combined expertise of three USC schools, scientists are developing a new drug aimed at a previously unexplored ...

Eisai and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA,of Australia has approved the humanized anti ...

Phoenix platform matches users with genetically similar people to predict which interventions actually work. SINGAPORE, July 18, 2025 (GLOBE NEWSWIRE) -- The Phoenix today launched the alpha version ...

On 23 September 2025 the TGA made the decision to approve the registration of the lecanemab (LEQEMBI).What is LEQEMBI ...

Voyager Therapeutics has unveiled a new program focused on Alzheimer’s disease (AD) that utilizes a proprietary IV-delivered TRACER™ capsid to target the APOE gene, specifically aiming to reduce the ...

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s ...

LEQEMBI is a monoclonal antibody that is administered in a specialised centre via a one-hour intravenous infusion every two weeks and targets the underlying pathology of Alzheimer's disease. 1,2 ...

Although her grandfather had dementia when he died, Kristin Richardson hadn’t worried much about her brain until a lab test revealed that she was positive for APOE4, a gene that has been linked to a ...

Although her grandfather had dementia when he died, Kristin Richardson hadn’t worried much about her brain until a lab test revealed that she was positive for APOE4, a gene that has been linked to a ...

Although her grandfather had dementia when he died, Kristin Richardson hadn’t worried much about her brain until a lab test revealed that she was positive for APOE4, a gene that has been linked to a ...